Article Sidebar
Published:
May 9, 2025Keywords:
Article Details
While African Health Sciences has been freely accessible online there have been questions on whether it is Open Access or not. We wish to clearly state that indeed African Health Sciences is Open Access. There are key issues regarding Open Access needing clarification for avoidance of doubt:
- 1. Henceforth, papers in African Health Sciences will be published under the CC BY (Creative Commons Attribution License) 4.0 International. See details on https://creativecomons.org/)
- 2. The copyright owners or the authors grant the 3rd party (perpetually and in advance) the right to disseminate, reproduce, or use the research papers in part or in full, format/medium as long as:
- No substantive errors are introduced in the process
- Attribution of authorship and correct citation details are given
- The referencing details are not changed.
Should the papers be reproduced in part, this must be clearly stated.
- 3. The papers will be freely and universally accessible online in an easily readable format such as XML in at least one widely recognized open access repository such as PUBMED CENTRAL.
B. ABRIDGED LICENCE AGREEMENT BETWEEN AUTHORS AND African Health Sciences
I submitted my manuscript to African Health Sciences and would like to affirm that:
1.0 I am authorized by my co-authors to enter into these arrangements.
2.0 I guarantee, on behalf of self and co-authors:
- That the paper is original, and has not been published in any other peer-reviewed journal; nor is it under consideration by other journal (s). It does not infringe existing copyright or any other person’s rights
- That we are/I am the sole author(s) of the paper and with authority to enter into this agreement. My granting rights to African Health Sciences is not in breach of any other obligation
- That the paper contains nothing unlawful, or libelous. Nor anything that would constitute a breach of contract, confidence or commitment given to secrecy, if published
- That I/we have taken care to ensure the integrity of the article.
3.0 I and all co-authors, agree that the paper, if accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0. (see https://creativecommons.org/)
Main Article Content
Phosphodiesterase 4 inhibitor combined with secukinumab relieves clinical symptoms in patients with psoriasis via regulating p38MAPK activation and the immune response inflammation
Abstract
Background: The purpose of the present study was to explore the effect of phosphodiesterase 4 (PDE-4) inhibitor combined with secukinumab monoclonal antibody on the activation level of p38 mitogen-activated protein kinases (p38MAPK) in psoriatic leukocytes.
Methodology: The clinical data of 60 patients with psoriasis were retrospectively analyzed, and they were divided into a control group (secukinumab monotherapy, 30 cases) and a study group (PDE-4 inhibitory therapy). Agent combined with secukinumab treatment(30 cases), all were treated for 3 months. The Psoriasis Area and Severity Index (PASI), clinical symptom score, serum inflammatory factors, p38MAPK gene expression in lesion tissue, and clinical outcome were compared between the two groups.
Results: After treatment, the PSAI score (t=5.051) and symptom score (t=14.102) of the study group were lower than those of the control group, and the relative expression of interleukin-6 (IL-6) (t=7.514) and p38MAPK (t=4.219), the relative expression of interleukin-17 (IL-17) (t=2.579) was lower than that of the control group. The total effective rate in the study group (83.33% vs. 60.00%) was higher than that in the control group.
Conclusion: Secukinumab along with phosphodiesterase 4 inhibitors reduces p38MAPK activation, and improves immune response, inflammation, and clinical symptoms in patients with psoriasis.
Keywords: Psoriasis; phosphodiesterase 4 inhibitor; secukinumab secukinumab; p38 MAPK.
